Avi-Dekel (cannabis oil 20:1) / Tikun Olam Cannbit Pharma - LARVOL DELTA

Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial. (PubMed, Front Med (Lausanne)) - P2 | "In this randomized controlled trial, 'Avidekel' oil significantly reduced agitation over placebo in patients suffering from behavioral disturbances related to dementia, with non-serious side-effects. Further research is required with a larger sample size."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Developmental Disorders • Mental Retardation • Psychiatry

Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder. (PubMed, Transl Psychiatry) - "Furthermore, we were able to uncover the involvement of CB1 receptor (CB1R) signaling in the Avidekel oil mechanism, alongside a mitigation of cerebrospinal fluid (CSF) glutamate concentrations. Subsequently, RNA sequencing (RNA seq) of cerebellar brain samples revealed changes in mRNA expression of several neurotransmission-related genes post-treatment. Finally, our results question the relevancy of CBD enrichment of medical cannabis for treating the core symptoms of ASD, and emphasize the importance of the THC component for alleviating deficits in repetitive and social behaviors in ASD."

Journal • Preclinical • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Mental Retardation • Mood Disorders • Psychiatry

Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: TO Pharmaceuticals; N=40 ➔ 0; Trial completion date: Dec 2019 ➔ Sep 2022; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Dec 2019 ➔ Sep 2022

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Dermatology • Hidradenitis Suppurativa

The Effect of Cannabis on Dementia Related Agitation and Aggression (clinicaltrials.gov) - P2; N=64; Completed; Sponsor: TO Pharmaceuticals; Recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • Dementia

FDA issues more warning letters regarding the marketing of cannabidiol-containing product (Lexology) - "The companies are being warned regarding unsubstantiated claims related to a number of different cannabidiol (CBD)-containing products. Each of the companies have made claims in their advertising that their products can treat or cure a number of diseases and health conditions, including cancer, Alzheimer’s disease...A failure to address the FTC’s concerns may result in legal action against the companies, including injunctions and orders to refund money to customers."

Clinical

Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice. (PubMed, Inflammopharmacology) - "No synergistic effect was observed by combining CBD or Avidekel extracts with Copaxone. Our data support the use of Avidekel extracts in the treatment of MS symptoms."

Journal • Preclinical